Among cancer patients receiving PD-1 inhibitor monotherapy (Fig. 1), treatment-related fatigue was more likely to occur in patients with melanoma (31.1 %, 95 % CI 29.7%–32.5 %). This evidence concerns the gene PDCD1 and melanoma.